AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$NUTX

Saunders Scott J sold $43K of NUTX

Saunders Scott J sold 203 shares of Nutex Health Inc. (NUTX) at $214.25 on 2026-09-18.

Original reporting
SEC EDGAR · Saunders Scott J
Published Sep 18, 2026, 6:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 6:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NUTX
Neutral
medium confidence
Mentioned
$NUTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUTXNeutralLow
01

Why it matters

The director's sale is modest and unlikely to move the stock, but traders may monitor for patterns.

02

Market read

Minor insider sale; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

Form 4 filing reports insider transactions to the SEC; this is the first public disclosure of this sale.

Company-level read

Ticker impact

$NUTXNeutralMedium confidence
Context

Director Scott J. Saunders sold 203 shares of Nutex Health for $43,492.75 on 2026-09-18.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

The transaction size is small relative to market cap and does not constitute a material event.

Market effects

Sector

No broader sector impact; health‑tech sector unchanged.

Regional

No regional effect.

Global

Not globally relevant.

Counterpoint

What could challenge this read

The sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    Nutex Health Inc.

    Health‑technology firm listed as NUTX.

  • Insider
    Saunders Scott J.

    Director of Nutex Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUTX insider trading history →

Related articles

AUG 25
$NUTXMed

Fifth Circuit Rejects "Ghost Rates" in Federal QPA Calculations Under the No Surprises Act

Nutex Health (NASDAQ: NUTX) commented on a Fifth Circuit ruling invalidating federal QPA calculation rules under the No Surprises Act, which the company says artificially deflated payments. The court ruled insurers cannot include non-negotiated 'ghost rates' and must include bonus payments in QPA calculations. Nutex Health expects this to lead to fairer upfront payments for providers. The ruling may impact the company's financials, but the timeline for new regulations is uncertain.

prnewswire.com2 min
AUG 13
$NUTXMedAI 8/10

Nutex Health (NUTX) Q2 2026 Earnings Call Transcript

Nutex Health (NUTX) reported Q2 2026 results on an earnings call. Total revenue fell to $210.8M from $244.0M. Net income rose to $65.8M, diluted EPS to $9.38, and adjusted EBITDA to $90.0M. Management cited lower contract services costs from a HaloMD amendment and higher patient visits, plus a hospital expansion pipeline.

fool.com7 min
AUG 10
$NUTXMedAI 8/10

Nutex Health Q2 Profit Soars As IDR Cost Reductions Drive Margin Gains

Nutex Health (NUTX) reported Q2 2026 results, with net income of $65.8M and diluted EPS of $9.38, versus a net loss of $17.7M a year earlier. Revenue fell 13.6% to $210.8M. The company cited IDR-related cost reductions, including a $52.3M contract services expense decline, and expects normalized historical expenses to drop 25% to 30% prospectively. Shares rose 14.88% to $186.19.

rttnews.com4 min
AUG 6
$NUTXMed

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.

prnewswire.com6 min
AUG 6
$NUTXMed

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2026. Nutex Health is a physi

SEC EDGAR 8-K7 min